Revenue $3.33B, up 12.5% on a year earlier. Total CF product revenues, net $3.21B, up 9.0%. TRIKAFTA/KAFTRIO product revenues $2.50B, down 2.1%. Diluted EPS $4.31 against $3.99.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $3.33B | $2.99B | $2.96B | +12.5% |
| Operating income | $1.25B | $1.14B | $1.15B | +8.3% |
| Net income | $1.10B | $1.03B | $1.03B | +6.5% |
| Diluted EPS | $4.31 | $4.02 | $3.99 | |
| Operating cash flow | $1.13B | $1.43B | $1.07B | +4.9% |
| Capital expenditures | -$112.20M | -$133.40M | -$145.70M | |
| Free cash flow | $1.01B | $1.29B | $927.40M | +9.3% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Total CF product revenues, net | $3.21B | $2.94B | +9.0% |
| TRIKAFTA/KAFTRIO product revenues | $2.50B | $2.55B | -2.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Vertex Pharmaceuticals Inc / Ma (VRTX) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/VRTX/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
